| 1 |
Safety of Allogeneic Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) to Treat Perianal Fistulas Patients With Crohn's Disease |
Perianal Fistula Due to Crohn's Disease|Fistula in Ano |
Biological: Human umbilical cord mesenchymal stem cells (UC-MSCs) |
CryoCord Sdn Bhd|University of Malaya |
Phase 1 |
NCT05039411 |
2022-03-01 |
| 2 |
Immunotherapy for Advanced Liver Cancer |
Hepatocellular Carcinoma |
Biological: AlloStim짰 immunotherapy|Drug: FOLFOX regimen|Other: Best Supportive Care |
Immunovative Therapies, Ltd.|Mirror Biologics, Inc. |
Phase 2|Phase 3 |
NCT05033522 |
2022-02-01 |
| 3 |
MK-1654 in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007) |
RSV Infection |
Biological: MK-1654|Biological: Palivizumab|Biological: Placebo |
Merck Sharp & Dohme LLC |
Phase 3 |
NCT04938830 |
2021-11-30 |
| 4 |
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure |
Carcinoma, Non-Small-Cell Lung |
Drug: Lazertinib|Drug: Amivantamab|Drug: Pemetrexed|Drug: Carboplatin |
Janssen Research & Development, LLC |
Phase 3 |
NCT04988295 |
2021-11-17 |
| 5 |
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) |
Colorectal Cancer |
Biological: favezelimab/pembrolizumab|Drug: regorafenib|Drug: TAS-102 |
Merck Sharp & Dohme LLC |
Phase 3 |
NCT05064059 |
2021-11-10 |
| 6 |
Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study |
COVID-19 Pandemic |
Biological: Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)|Biological: Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) |
Livzon Pharmaceutical Group Inc. |
Phase 3 |
NCT05096832 |
2021-11-03 |
| 7 |
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent |
Arthritis, Psoriatic |
Drug: Guselkumab|Drug: Placebo |
Janssen Research & Development, LLC |
Phase 3 |
NCT04936308 |
2021-09-28 |
| 8 |
Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents |
COVID-19 |
Biological: Inactivated COVID-19 Vaccine|Biological: Controlled vaccine |
Sinovac Research and Development Co., Ltd.|Sinovac Biotech Co., Ltd |
Phase 3 |
NCT04992260 |
2021-09-10 |
| 9 |
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) |
Breast Neoplasms |
Biological: pembrolizumab|Drug: paclitaxel|Drug: nab-paclitaxel|Drug: liposomal doxorubicin|Drug: capecitabine|Drug: normal saline|Drug: dextrose |
Merck Sharp & Dohme LLC |
Phase 3 |
NCT04895358 |
2021-06-18 |
| 10 |
Atacicept in Subjects With IgA Nephropathy |
IgA Nephropathy|Berger Disease |
Biological: Atacicept|Other: Placebo to match Atacicept |
Vera Therapeutics, Inc. |
Phase 2 |
NCT04716231 |
2021-05-18 |
이 누리집은 대한민국 공식 전자정부 누리집입니다.